Addressing the challenge: current and future directions in ovarian cancer therapy

Area of Science:

• Oncology
• Gene Therapy
• Nanotechnology

Background:

• Ovarian gene therapy strategies are advancing in clinical trials, targeting deregulated genes, immune response, and tumor growth.
• Non-viral delivery systems present advantages over viral vectors for therapeutic gene delivery in ovarian cancer.

Purpose of the Study:

• To provide a comprehensive review of non-viral delivery systems for ovarian gene therapy.
• To explore optimized DNA constructs and administration routes for enhanced ovarian cancer treatment.
• To discuss strategies for overcoming cellular and nuclear barriers for improved therapeutic outcomes.

Main Methods:

• Review of current non-viral gene delivery formulations: naked DNA, liposomes, polyplexes, nanoparticles, gene gun, and ultrasound/microbubble methods.
• Evaluation of minicircle DNA (using minimal immunological defined gene expression technology) as a safe and effective alternative to plasmids.
• Discussion of targeted delivery approaches using folate modification, nuclear localization signals, and PEGylated stealth liposomes.

Main Results:

• Non-viral methods show potential for improved biosafety, gene transfer, and reduced immune response compared to traditional vectors.
• Minicircles offer advantages in terms of bioavailability, size, and minimal immune reaction for ovarian gene therapy.
• Targeted delivery systems enhance selective tumor targeting and minimize systemic toxicity.

Conclusions:

• Non-viral delivery systems, particularly advanced formulations like minicircles and targeted liposomes, are crucial for effective ovarian cancer gene therapy.
• Optimizing DNA constructs and administration routes is essential for overcoming treatment challenges posed by peritoneal dissemination.
• Further exploitation of targeted delivery strategies can significantly enhance the therapeutic index while minimizing toxicity in ovarian cancer patients.